Pulmonx Corporation LUNG Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price at other companies

Espey Manufacturing & Electronics Corp.ESP

5.4+13.4%

General DynamicsGD

$217.50+5.8%

WaFd, Inc.WAFD

$7.53+36.9%

American Battery Technology CompanyABAT

$1.90—

Tarsus Pharmaceuticals, Inc.TARS

$47.13+56.3%

Phillips 66PSX

$90.11+0.9%

Other financials

Income statement

See full

Revenue$20.6M-8.7%

Gross profit$16.0M-1.8%

Operating income-$13.0M+11.0%

Net income-$13.7M+5.5%

EPS (diluted)-$0.33+8.3%

Balance sheet

See full

Cash & equivalents$61.0M-2.4%

Total debt$56.3M-1.2%

Total equity$45.8M-41.1%

Total assets$120.0M-20.4%

Cash flow

See full

Operating cash flow-$10.1M+23.6%

CapEx$9.0K-97.0%

Free cash flow-$10.1M+25.3%

Valuation

See full

Market cap$54.91M-43.7%

Enterprise value$50.17M-39.2%

P/S0.6×-0.5×

Profitability

See full

Gross margin75.5%+2.0pp

Operating margin-58.8%-5.8pp

Net margin-60.1%-4.4pp

FCF margin-33.2%-4.4pp

Returns & leverage

See full

Return on equity-86.2%+62.6pp

Debt / equity1.2×+0.5×

Current ratio4.9×-0.1×

Where this comes from

Reported directly by Pulmonx Corporation in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice.

The official record: Pulmonx Corporation’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pulmonx Corporation's share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, weighted average exercise price.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Pulmonx Corporation's share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, weighted average exercise price?: Pulmonx Corporation (LUNG) reported share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, weighted average exercise price of $16.73 in Q1 2026.
How has Pulmonx Corporation's share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, weighted average exercise price changed year-over-year?: Pulmonx Corporation's share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, weighted average exercise price increased by 16.5% year-over-year, from $14.36 to $16.73.